Non-Small-Cell Lung Cancer | Treatment Sequencing | US | 2021
KEY BENEFITS AND USES
- Pinpoint current drug positioning and uptake in one snapshot to facilitate forecasting.
- Drill down into physicians’ treatment sequences and understand who to position against and how to defend share.
- Identify untapped treatment scenarios and key competitors to aid trial design.
- Evaluate unique disease-specific treatment patterns and dynamics to plan and manage sales and marketing resources and execute commercialization messages.
- Discover untapped populations to expand product share and drive strategic decisions.
QUESTIONS ANSWERED
- Where is my product positioned versus competitors’ products in the treatment journey?
- What are physicians’ most frequent treatment sequences? Who is benefiting, and how can I defend my asset’s share and position?
- What are the market-relevant treatment scenarios, according to oncology experts?
- Where are the untapped business opportunities on which I can capitalize?
- How can I optimize trial design and ensure a competitive edge for my pipeline asset?
GEOGRAPHIES
United States
PRIMARY MARKET RESEARCH
Survey of ~100 U.S. medical oncologists
PRODUCT DESCRIPTION
Treatment Sequencing provides disease-specific, sequential treatment patterns in market-relevant treatment scenarios and drug share mapped to the treatment journey. The quantitative sequencing analysis illuminates drug positioning through primary market research-based insights from physicians.
Related Market Assessment Reports
Report
Scleroderma (Systemic Sclerosis) – Current Treatment – Treatment Algorithms: Claims Data Analysis – Scleroderma (Systemic Sclerosis) (US)
Scleroderma (systemic sclerosis, SSc) is a rare, progressive autoimmune disease marked by skin fibrosis, systemic inflammation, and vasculopathy, leading to Raynaud’s phenomenon and painful…
Report
Bladder Cancer and Upper Tract Urothelial Carcinoma – Geographic Focus: China – Bladder Cancer and Upper Tract Urothelial Carcinoma – China In-Depth – China
China’s bladder cancer market is entering a period of accelerated expansion, as novel branded therapies reshape systemic management. A major growth driver is the expanding role of immune…
Report
Squamous Cell Carcinoma of the Head and Neck – Geographic Focus: China – China In-Depth – Squamous Cell Carcinoma of the Head and Neck
China’s SCCHN market is undergoing rapid transformation, driven by the expanding use of systemic therapies beyond traditional surgery and radiotherapy. Current treatment options include…
